Premium
Rhodanine Derivatives as Selective Protease Inhibitors Against Bacterial Toxins
Author(s) -
Johnson Sherida L.,
Chen LiHsing,
Harbach Rebecca,
Sabet Mojgan,
Savinov Alexei,
Cotton Naomi J. H.,
Strongin Alex,
Guiney Donald,
Pellecchia Maurizio
Publication year - 2008
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/j.1747-0285.2007.00617.x
Subject(s) - rhodanine , proteases , chemistry , in vitro , protease , in vivo , drug discovery , bacillus anthracis , microbiology and biotechnology , biology , biochemistry , enzyme , bacteria , genetics
In this study, we analyzed a series of rhodanine derivatives, as potential inhibitors of bacterial toxins, namely the proteases anthrax lethal factor and the botulinum neurotoxin type A. Conducting an extensive structure–activity relationship study on rhodanine derivatives, we profiled their selectivity against the two bacterial toxins and two related human metalloproteases using in vitro assays. In addition, we examined initial in vitro ADME‐Tox properties of selected compounds and their ability to protect lethal factor‐induced cell death of macrophages. These data allowed the selection of one additional drug candidate for which preliminary in vivo efficacy studies against anthrax spores were conducted. Integration of these results with our structure–activity relationship studies provides a framework for the development of potential drug candidates against anthrax and botulinum.